Najlepsi lekarze w Hiszpanii — proszę uzyskać konsultację online

Dr. Jordi Coromina Isern is a respected otolaryngologist with over 30 years of experience. He specializes in treating ENT diseases. He is skilled in advanced surgeries, including cochlear implants, septoplasty, tonsillectomy, tympanoplasty, and cleft lip or palate repair.

Dr. Coromina is known for introducing laser and Da Vinci robotic surgeries in ENT care. He has received the César Bertrán Award from the Spanish Society of Otolaryngology. He also received an award from the Catalan Society of Pulmonology for his clinical achievements.

He is a member of several leading medical societies. He completed his medical training with honors and gained international experience at institutions such as Mayo Clinic and Boston Children's Hospital.

Dr. Guillermo Luis Bassols earned his degree in Medicine and Surgery from the Universidad Autónoma de Barcelona. He is a specialist in Obstetrics and Gynecology. He has over 30 years of clinical experience. Dr. Bassols has worked in top hospitals and clinics in Barcelona. He has been part of Centro Médico Teknon since 1999.

He completed his residency at Institut Universitari Dexeus. He also holds a European Certificate in Endoscopic Surgery in Gynecology from the University of Clermont-Ferrand. Dr. Bassols has made important contributions to women’s health. He is highly skilled in minimally invasive gynecological surgery and obstetric care.

Dr. Jaime De La Torre Rojo is a specialist in Orthopedic Surgery and Traumatology. He is known for his advanced skills in arthroscopic techniques. He has published research in the Revista Iberoamericana de Cirugía de la Mano. His work includes studies on surgical outcomes for elderly patients with distal radius fractures.

Dr. De La Torre Rojo treats articular fractures of the radius and scaphoid, as well as ligament injuries of the carpus. He also performs complex knee procedures. These include knee arthroscopy, anterior cruciate ligament reconstruction, knee replacement, knee arthroplasty, and unicompartmental knee replacement. His clinical work and research have made him a respected expert in his field.

Onkolog, Specjalista w leczeniu raka skóry

Radioonkolog

Chirurg ogólny i układu pokarmowego ze specjalizacją w małoinwazyjnej chirurgii laparoskopowej. Zajmował stanowiska Associate Clinical Lecturer i Lecturer w University of Navarre School of Medicine. Członek Spanish Association of Surgeons, Spanish Society of Obesity Surgery i European Association for Endoscopic Surgery.

Dr. Lana Bijelic is a board-certified oncological surgeon. She specializes in peritoneal carcinomatosis. Since 2019, she has been part of the Carcinomatosis Surgical Group at the Teknon Oncology Institute. She trained under Prof. Paul Sugarbaker at Washington Hospital Center and brings strong expertise to her team.

Dr. Bijelic has worked as Research Director at Inova Fairfax Hospital. She has also been an associate professor at Virginia Commonwealth University and Georgetown University. She is an active member of the American College of Surgeons and the Society of Surgical Oncology.

Throughout her career, Dr. Bijelic has received many academic awards, including several Surgical Excellence Awards and top prizes in research. She is known for her leadership and important contributions to surgical oncology.

Dr. Jose Maria Raventos is a surgeon with 49 years of experience. He specializes in general, abdominal, endocrine, and thyroid surgery. He is known for his advanced laparoscopic skills. Dr. Raventos is also highly experienced in thyroid surgery, including complex thyroid cancer cases.

He has made important contributions to surgical research and education. He has published many scientific articles and is active in several professional associations. Dr. Raventos earned his medical degrees from the University of Barcelona and the University of Minnesota. He completed his residencies at the Red Cross Hospital of Barcelona and the Mayo Clinic in Rochester. He is a founding member of the Teknon Medical Center faculty and the Surgical Associate Surgeons group.

Dr Moises ukończył Wydział Lekarski Universidad Nacional de Tucumán w 1992 r., uzyskując tytuł z medycyny i chirurgii. Specjalizował się w nefrologii i obronił rozprawę doktorską w 1995 r. Otrzymał również grant badawczy od Universidad Nacional de Tucumán en Médico. Był specjalistą w Oddziale Transplantacyjnym Hospital Clínic de Barcelona w latach 1995–2000 oraz wiodącym specjalistą w Oddziale Medycyny Wewnętrznej Teknon w latach 2004–2009. Obecnie jest kierownikiem tego wydziału i członkiem różnych organizacji, w tym Hiszpańskiego Towarzystwa Nefrologicznego, Hiszpańskiego Towarzystwa Nadciśnienia Tętniczego i Katalońskiego Towarzystwa Nadciśnienia Tętniczego.

Odkryto genetyczną przyczynę rzadkiego zespołu powodującego nagłą śmierć serca, nazwanego później zespołem Brugadów.
Wykonał ponad 25 000 ablacji serca.
Opublikował ponad 350 prac naukowych z zakresu kardiologii.
Przeszkolono ponad 200 specjalistów.
Odbywa coroczne podróże do Afryki, aby leczyć dzieci cierpiące na arytmię.

CURRICULUM VITAE

VOLKERT B. WREESMANN MD PhD

Consultant Otolaryngologist

Oncologic Head and Neck Surgeon

Thyroid and Parathyroid Surgeon

Facial Plastic Surgeon

Principal Positions

• Centro Medico Teknon, Barcelona, Spain

Chairman, Department of Otolaryngology-Head and Neck Surgery

July 1st 2024 – present

• Juaneda, Ciutadella Menorca, Spain

Consultant Otolaryngologist-Head and Neck Surgeon

January 2025 – present

• Avantmedic, Lleida, Spain

Consultant Otolaryngologist-Head and Neck Surgeon

July 1st 2024 – present

• Clinica Omega Zeta, Andorra

Consultant Otolaryngologist-Head and Neck Surgeon

March 1st 2022 – present

• University Hospitals Dorset NHS Foundation Trust

Consultant Otolaryngologist-Head and Neck Surgeon

August 1st 2021 – October 1st 2023

• Oxford University Hospitals NHS Foundation Trust

Honorary Consultant Otolaryngologist-Head and Neck Surgeon

May 1st 2021 – April 30th 2024

• Portsmouth Hospitals University NHS Trust, Portsmouth, UK

Consultant Otolaryngologist-Head and Neck Surgeon

July 18th 2016 – April 30th 2021

• Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

Consultant Otolaryngologist-Head and Neck Surgeon

November 7th 2015 – May 31st 2016

• Heart of England NHS Trust, Birmingham, UK

Consultant Otolaryngologist-Head and Neck Surgeon

March 1st 2015 – October 31st 2015

• University Medical Center Utrecht, Netherlands

Consultant Otolaryngologist-Head and Neck Surgeon

November 1st 2013 – June 1st 2014

Memberships

• American Head and Neck Society – Member

Netherlands Academy of Otolaryngology - Member

Professional Licences

• United Kingdom

GMC Certification

Fully Registered Medical Practitioner with Specialist Registration with a License to Practice

Registered: 02/02/2015

GMC # 7499626

• United States of America

New York State Department of Health

New York State Education Department

Registered: July 2011

License# P80949

Physician

• Netherlands

Dutch Ministry of Health (BIG Registration)

BIG Registered: 22-06-2005

BIG #19063373601

Physician

Dutch Specialist Board (RGS)

RGS registered: 01-02-2011

RGS #1911979

Otolaryngology-Head and Neck Surgeon

• Spain

Collegi de Metges de Barcelona

COMB: 63638

• Andorra

Collegi de Metges d’Andorra

RPS: 03098

COMA: 876

Education

• Memorial Sloan-Kettering Cancer Center

Surgical Fellowship, Head and Neck Surgery

New York, New York, USA

August 1st 2011 - July 31st 2013

600 bed dedicated cancer center

Performed 1200 major oncologic head and neck resections in 2 years

• United States of America ECFMG Certification

United States Medical Licensing Examination (USMLE)

Certification: June 22nd, 2010

Scores: 

   Step I: 244/99 

   Step IIa-Clinical knowledge: 227/94

   Step IIb-Clinical Skills: PASSED

   Step III: 206/85

• Netherlands Cancer Institute

Surgical Fellowship, Head and Neck Surgery

Amsterdam, The Netherlands

February 1st 2011 - July 31st 2011

Specialized Head and Neck Cancer Surgery Department

200 bed hospital

• Amsterdam University Medical Center/Netherlands Cancer Institute

Residency Training, Otolaryngology-Head and Neck Surgery

Amsterdam, the Netherlands

February 1st 2006 – January 31st 2011

• University of Amsterdam School of Medicine

Medical Doctor (MD)

Amsterdam, the Netherlands

December 2002 - January 28th 2005

• University of Amsterdam

Doctor of Philosophy (PhD), Molecular Biology

Amsterdam, the Netherlands

Thesis title: Molecular-cytogenetic characterization of head and neck cancer

December 2nd, 2004

• Erasmus University School of Medicine

Doctoral Degree in Medicine

Rotterdam, the Netherlands

September 1994 - November 17th, 1998

Research Training

• Memorial Sloan-Kettering Cancer Center

Laboratory of Epithelial Cancer Biology, Head and Neck Service, Department of Surgery, New York, New York, USA

Research Fellowship in Molecular Oncology

Supervisors: Dr. Bhuvanesh Singh MD, PhD and Dr. Jatin P. Shah, MD, FACS

March 1st 1999 - September 30st 2002

• University of California San Francisco (UCSF)

Department of Otolaryngology-Head and Neck Surgery, San Francisco, California, USA

Post-doctoral Research Fellowship in Head and Neck Oncology

Supervisors: Dr. Steven Wang MD And Prof David Eisele MD

February 2005 - January 2006

Academic Activities

University of Amsterdam

Doctorate Examination Committee member

• September 17th, 2013 - PhD Candidate: Dr. I.J. Nixon (United Kingdom)
• October 17th 2014 - PhD Candidate: Dr. J. Pramana (Netherlands)
• November 17th 2015 - PhD candidate: Dr. H. van Monsjou (Netherlands)
• December 11th 2018 - PhD Candidate: Dr. Tihana Ibrahimpasic (United States)
• January 18th, 2021 - PhD Candidate: Dr. Laura Wang (Australia)
• June 2nd, 2021 - PhD Candidate: Dr. Caroline Verhagen (Netherlands)

Conference Faculty

• Advanced Laryngopharyngeal Cancer: Functional Preservation and Rehabilitation, Portsmouth, June 25th - 26th, 2020 (postponed due to COVID) - Chairman
• Functional Preservation and Rehabilitation after Treatment for Advanced Laryngeal Cancer, Portsmouth, March 14th - 15th, 2019 - Chairman
• Portsmouth Parathyroid Conference, Portsmouth, December 14th 2018 – Chairman

Editorial Roles

• European Journal of Surgical Oncology

Associate Editor

January 1st 2023 – present

• European Journal of Surgical Oncology

Guest Editor

March issue 2018, Volume 44, Issue 3, p275-378 - Special issue on thyroid cancer management

• Journal of Oral Pathology and Medicine

Guest Editor

November issue 2021, Volume 51, Issue 10 - Special issue on vascular malformations and tumors of the head and neck

• Scientific Journal Reviewer

Oral Oncology, European Journal of Surgical Oncology, Journal of Surgical Oncology, Head and Neck, International Journal of Cancer

• Scientific Project and Grant Reviewer

Netherlands: Dutch Cancer Society

France: Institute National du Cancer

Awards

• New York Head and Neck Society

Annual Meeting, New York, NY, March 2002

Title of study presented: “MUC1 is a target if 1q amplification and pertains a grave clinical prognosis in papillary thyroid cancer”

Invited Lectures

• European Society of Surgical Oncology meeting, Krakow, 2016
• Barcelona Society of Neurosurgery, Annual Meeting, Baqueira, Spain, February, 2017
• University of Edinburgh, Department of Otolaryngology Academic Conference, March 17th 2017
• Medilex: Performance of Medical Specialists, Zeist, Netherlands, November 9th 2017
• Medilex: Performance of Medical Specialists, Driebergen, Netherlands, October 11th 2017
• Wessex Head and Neck and Thyroid Network Education Day, May 3rd, 2017
• Portsmouth Parathyroid Conference, Portsmouth, UK, December 14th 2018
• Global Post-laryngectomy Rehabilitation Academy, Portsmouth, UK, March 14th 2019
• Health Care Quality Conference, Beverwijk, Netherlands, March 25th, 2019

Published Research Reports

• The growing precision of diagnostic pathways in thyroid nodule evaluation. 

Bekker J, Wreesmann VB. 

Eur J Surg Oncol. 2025 Jan;51(1):109374.

• Special issue: Management of vascular tumors and malformations of the head and neck. 

Oomen KPQ, Brennan PA, Wreesmann VB. 

J Oral Pathol Med. 2022 Nov;51(10):829.

• Angiosarcomas of the head and neck: Impact of large data analysis on clinical management.
•  
• Wreesmann VB, Oomen KP, Brennan PA.

J Oral Pathol Med. 2022 Nov;51(10):904-910.

• Current classification of vascular anomalies of the head and neck. 

Oomen KPQ, Wreesmann VB. 

J Oral Pathol Med. 2022 Nov;51(10):830-836.

• A novel classification of carotid body tumors.

Wreesmann VB, Nixon IJ. 

Eur. J. Surg. Oncol. May, 2021

• Management of the contralateral central neck in differentiated thyroid cancer: A contentious issue. 

Shaha AR, Tuttle RM, Wreesmann VB. 

Eur. J. Surg. Oncol. 2021 Apr;47(4):717-719.

• Improvement of oral cancer screening quality and reach: The promise of artificial intelligence.
•  
• Kar A, Wreesmann VB, Shwetha V, Thakur S, Rao VUS, Arakeri G, Brennan PA.

J Oral Pathol Med. 2020 Mar 11

• The risk-benefit ratio of chemoradiation treatment in head and neck squamous cell carcinoma: value of extranodal spread and margin status. 

Ammar M, Wreesmann VB. 

Journal of ENT Masterclass, Yearbook 2018, Volume 11, Nr. 1, December 1st, 2018

• Nasal obstruction secondary to an inverted midline supernumerary tooth. 

Jones L, Hilton JM, Heyman J, Viswanathan H, Wreesmann VB, Hayes SM. 

Ann R Coll Surg Engl. 2019 Jan;101(1)

• Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects in vitro and poor outcome in patients with advanced head and neck squamous cell carcinoma. 

Verhagen CVM, Vossen DM, Borgmann K, Hageman F, Grénman R, Verwijs-Janssen M, Mout L, Kluin RJC, Nieuwland M, Severson TM, Velds A, Kerkhoven R, O'Connor MJ, van der Heijden M, van Velthuysen ML, Verheij M, Wreesmann VB, Wessels LFA, van den Brekel MWM, Vens C. 

Oncotarget. 2018 Apr 6;9(26):18198-18213.

• Complete nasal obstruction secondary to pacemaker insertion. 

Jones TL, Wreesmann VB, Nilssen E, Hilton J, Hayes SM. 

Ann R Coll Surg Engl. 2018 May;100(5)

• Optimization of the risk-benefit ratio of differentiated thyroid cancer treatment. 

Nasef HO, Nixon IJ, Wreesmann VB. Eur J Surg Oncol. 

2018 Mar;44(3):276-285. Review.

• The risk/benefit ratio of differentiated thyroid cancer treatment: Exploring treatment de-escalation. 

Wreesmann VB; on behalf of EJSO. 

Eur J Surg Oncol. 2018 Mar;44(3):275.

• Aggressive differentiated thyroid cancer. 

Janjua N, Wreesmann VB. 

Eur J Surg Oncol. 2018 Mar;44(3):367-377. Review.

• Role of extracapsular nodal spread and surgical margin status in defining high-risk head and neck squamous cell carcinoma and its treatment intensity. 

Wreesmann VB. 

International Journal of Head and Neck Surgery, April-June 2017; 8(2): 76-83.

• An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer.              

Nixon IJ, Wang LY, Migliacci JC, Eskander A, Campbell MJ, Aniss A, Morris L, Vaisman F, Corbo R, Momesso D, Vaisman M, Carvalho A, Learoyd D, Leslie WD, Nason RW, Kuk D, Wreesmann V, Morris L, Palmer FL, Ganly I, Patel SG, Singh B, Tuttle RM, Shaha AR, Gönen M, Pathak KA, Shen WT, Sywak M, Kowalski L, Freeman J, Perrier N, Shah JP. 

Thyroid. 2016 Mar;26(3):373-80.

• Influence of extracapsular nodal spread extent on prognosis of oral squamous cell carcinoma. 
•  
• Wreesmann VB, Katabi N, Palmer FL, Montero PH, Migliacci JC, Gönen M, Carlson D, Ganly I, Shah JP, Ghossein R, Patel SG.

Head Neck. 2016 Apr;38 Suppl 1:E1192-9.

• Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer. 

Nixon IJ, Kuk D, Wreesmann V, Morris L, Palmer FL, Ganly I, Patel SG, Singh B, Tuttle RM, Shaha AR, Gönen M, Shah JP. 

Ann Surg Oncol. 2015 Jul 28.

• Prognostic value of vascular invasion in well-differentiated papillary thyroid carcinoma.
•  
• Wreesmann VB, Nixon IJ, Rivera M, Katabi N, Palmer F, Ganly I, Shaha AR, Tuttle RM, Shah JP, Patel SG, Ghossein RA.

Thyroid. 2015 May;25(5):503-8.

• Head and neck squamous cell carcinoma in young patients.

van Monsjou HS, Wreesmann VB, van den Brekel MW, Balm AJ. 

Oral Oncol. 2013 Dec;49(12):1097-102.

• Oral and oropharyngeal squamous cell carcinomas in young patients: The Netherlands Cancer Institute experience. 

van Monsjou HS, M Lopez-Yurda, M. Hauptmann, Balm AJ, van den Brekel MM, Wreesmann VB. 

Head Neck. 2013 Jan;35(1):94-102.

• Oropharyngeal squamous cell carcinoma: a unique disease on the rise?

van Monsjou HS, Balm AJ, van den Brekel MM, Wreesmann VB. 

Oral Oncol. 2010 Nov;46(11):780-5.

• Closure of tracheoesophageal fistula with prefabricated revascularized bilaminar radial forearm free flap.

Wreesmann VB, Smeele LE, Hilgers FJ, Lohuis PJ. 

Head Neck. 2009 Jun;31(6):838-42.

• Clinical impact of molecular analysis on thyroid cancer management.

Wreesmann VB, Singh B. 

Surg Oncol Clin N Am. 2008 Jan;17(1):1-35.

Genetic abnormalities associated with chemoradiation resistance of head and neck squamous cell carcinoma. 

van den Broek GB, Wreesmann VB, van den Brekel MW, Rasch CR, Balm AJ, Rao PH. 

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4386-91.

• Association of CD44 V3-containing isoforms with tumor cell growth, migration, matrix metalloproteinase expression, and lymph node metastasis in head and neck cancer.

Wang SJ, Wreesmann VB, Bourguignon LY. 

Head Neck. 2007 Jun;29(6):550-8.

• Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma.
•  
• Wreesmann VB, Estilo C, Eisele DW, Singh B, Wang SJ.

ORL J Otorhinolaryngol Relat Spec. 2007;69(4):218-25. Epub 2007 Apr 4.

• Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression.
•  
• Saltman B, Singh B, Hedvat CV, Wreesmann VB, Ghossein R.
•  
• Surgery. 2006 Dec;140(6):899-905; discussion 905-6.

• Repetitive endoscopic sinus surgery failure: a role for radical surgery?

Videler WJ, Wreesmann VB, van der Meulen FW, Knegt PP, Fokkens WJ. 

Otolaryngol Head Neck Surg. 2006 Apr;134(4):586-91.

• MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas.
•  
• Patel KN, Maghami E, Wreesmann VB, Shaha AR, Shah JP, Ghossein R, Singh B.
•  
• Surgery. 2005 Dec;138(6):994-1001; discussion 1001-2.

• Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: biologic insights and clinical opportunities.

Wreesmann VB, Singh B. 

J Oral Pathol Med. 2005 Sep;34(8):449-59. Review.

• Molecular profiling of tumor progression in head and neck cancer.
•  
• Belbin TJ, Singh B, Smith RV, Socci ND, Wreesmann VB, Sanchez-Carbayo M, Masterson J, Patel S, Cordon-Cardo C, Prystowsky MB, Childs G.
•  
• Arch Otolaryngol Head Neck Surg. 2005 Jan;131(1):10-8.

• Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck.

Wreesmann VB, Shi W, Thaler HT, Poluri A, Kraus DH, Pfister D, Shaha AR, Shah JP, Rao PH, Singh B. 

J Clin Oncol. 2004 Oct 1;22(19):3965-72.

• Follicular variant of papillary thyroid carcinoma: genome-wide appraisal of a controversial entity.

Wreesmann VB, Ghossein RA, Hezel M, Banerjee D, Shaha AR, Tuttle RM, Shah JP, Rao PH, Singh B. 

Genes Chromosomes Cancer. 2004 Aug;40(4):355-64.

• Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker.

Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky M, Shaha AR, Kraus D, Shah JP, Rao PH, Ghossein R, Singh B. 

Cancer Res. 2004 Jun 1;64(11):3780-9.

• Genetic abnormalities associated with nodal metastasis in head and neck cancer.

Wreesmann VB, Wang D, Goberdhan A, Prasad M, Ngai I, Schnaser EA, Sacks PG, Singh B. 

Head Neck. 2004 Jan;26(1):10-5.

• Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients.
•  
• Kutler DI, Wreesmann VB, Goberdhan A, Ben-Porat L, Satagopan J, Ngai I, Huvos AG, Giampietro P, Levran O, Pujara K, Diotti R, Carlson D, Huryn LA, Auerbach AD, Singh B.
•  
• J Natl Cancer Inst. 2003 Nov 19;95(22):1718-21.

• Chromosomal aberrations in patients with head and neck squamous cell carcinoma do not vary based on severity of tobacco/alcohol exposure.

Singh B, Wreesmann VB, Pfister D, Poluri A, Shaha AR, Kraus D, Shah JP, Rao PH. 

BMC Genet. 2002 Nov 14;3:22. Epub 2002 Nov 14.

• Genome-wide appraisal of thyroid cancer progression.
•  
• Wreesmann VB, Ghossein RA, Patel SG, Harris CP, Schnaser EA, Shaha AR, Tuttle RM, Shah JP, Rao PH, Singh B.
•  
• Am J Pathol. 2002 Nov;161(5):1549-56.

• Refractory chronic sinusitis: evaluation of symptom improvement after Denker’s procedure.
•  
• Wreesmann VB, Fokkens WJ, Knegt PP.
•  
• Otolaryngol Head Neck Surg. 2001 Nov;125(5):495-500.

• Inflammatory pseudotumour (inflammatory myofibroblastic tumour) of the pancreas: a report of six cases associated with obliterative phlebitis.
•  
• Wreesmann V, van Eijck CH, Naus DC, van Velthuysen ML, Jeekel J, Mooi WJ.
•  
• Histopathology. 2001 Feb;38(2):105-10.

• Screening for genetic aberrations in papillary thyroid cancer by using comparative genomic hybridization.
•  
• Singh B, Lim D, Cigudosa JC, Ghossein R, Shaha AR, Poluri A, Wreesmann VB, Tuttle M, Shah JP, Rao PH.
•  
• Surgery. 2000 Dec;128(6):888-93;discussion 893-4.

Abstracts (Presentations at scientific meetings):

• Genome-wide screening for genetic prognostic factors in papillary thyroid carcinoma.
•  
• Wreesmann VB, Ghossein RA, Poluri A, Shaha AR, Tuttle RM, Shah JP Rao PH, Singh B.

Fifth International Conference on Head and Neck Cancer San Francisco, CA, July 2000.

• Hierarchical Clustering (HC): a Novel Approach to Evaluating the Prognostic Value of Laboratory Parameters in Patients (Pts) Undergoing Chemoradiation Treatment (CRT) for Advanced Laryngopharyngeal Carcinoma (LPC). 

Singh B, Pfister D, Wreesmann VB, Li R, Gogineni S, Bosl G, Hoffman RH, Shah JP, Rao PH. 

37th Annual Meeting of the American Society of Clinical Oncology; New Orleans LA, May 2001.

• Gain of 1q is unique to the tall cell variant of papillary thyroid cancer.

Wreesmann VB, Ghossein RA, Tuttle RM, Shaha AR, Robbins R, Shah JP, Rao PH, Singh B. 

73rd annual meeting of the American Thyroid Association, Washington D.C. November 2001.

• MUC1 is a target of 1q amplification and pertains a grave clinical prognosis in papillary thyroid cancer. 

Wreesmann VB, Sieczka E, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Shah JP, Rao PH, Ghossein RG, Singh B. 

Annual Meeting of the New York Head and Neck Society, New York, NY, March 2002.

• Genome wide screening identified gains and losses as independent prognostic variables in patients with head and neck squamous cell carcinoma (HNSCC). 

Singh B, Wreesmann VB, Thaler HT, Shi W, Shah JP, Shaha AR, Kraus DH, Boyle JO, Pfister D, Rao PH. 

38th Annual Meeting of the American Society of Clinical Oncology; Orlando, Fl May 2002.

• p53 inactivation by human papillomavirus (HPV) in Fanconi anemia associated squamous cell carcinoma. 

Kutler DI, Goberdhan A, Wreesmann VB, Giampietro PF, Auerbach AD, Singh B. 

The Sixth Research Workshop on the Biology, Prevention, and Treatment of Head and Neck Cancer; Washington D.C.; October 2002.

• Identification of novel prognostic factors in head and neck squamous cell carcinoma. 
•  
• Wreesmann VB, Shi W, Thaler HT, Shah JP, Shaha AR, Kraus DH, Boyle JO, Pfister D, Rao PH, Singh B. 

7th symposion on Research in Head and Neck Cancer; Dusseldorf, Germany, September 4-6 2003.

• Molecular profiling of aggressive papillary thyroid cancer: prognostic significance of MUC1 alterations. 

Wreesmann VB, Sieczka E, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky M, Shaha AR, Kraus D, Shah JP, Rao PH, Ghossein RA, Singh B. 

7th symposion on Research in Head and Neck Cancer; Dusseldorf, Germany, September 4-6 2003.

• Chromosomal aberrations in Fanconi anemia-associated squamous cell carcinomas differ from sporadic squamous cell carcinomas from the general population. 

Kutler DI, Rao PH, Wreesmann VB, Goberdhan A, Ngai I, Huvos AG, Giampietro PF, Levran O, Pujara K, Diotti R, Auerbach AD, Singh B. 

15th annual Fanconi Anemia Research Fund scientific symposium, Houston TX, Oct 2003.

• Molecular classification of Fanconi anemia(FA)-associated head and neck squamous cell carcinoma (HNSCC) using oligonucleotide microarrays. 

Kutler DI, Ganly I, Wreesmann VB, Goberdhan A, Ngai I, Huvos AG, Giampietro PF, Levran O, Pujara K, Diotti R, Auerbach AD, Singh B. 

15th annual Fanconi Anemia Research Fund scientific symposium, Houston TX, Oct 2003.

•  
• Genotyping follicular cell-derived thyroid neoplasia: a CGH study of 150 cases.

Wreesmann VB, Ghossein RA, Socci N, Shaha AR, Tuttle RM, Shah JP, Rao PH, Singh B. 

Sixth International Conference on Head and Neck Cancer, Washington DC, August 2004.

• Downregulation of Fanconi anemia genes in sporadic squamous cell carcinomas of the head and neck. 

Wreesmann VB, Estilo C, Eisele DW, Singh B, Wang SJ. 

208th meeting of the Netherlands Society of Otolaryngology-Head and Neck Surgery, Utrecht, April 7th 2006.

• Extracapsular nodal spread does not predict outcome in clinically node negative oral cavity squamous cell carcinoma. 

Wreesmann VB, Ghossein RA, Carlson D, Ganly I, Palmer F, Montero P, Shah JP, Patel SG. 

AHNS 2013 Annual Meeting, April 10 & 11, 2013, Orlando Florida.

• Minor (<2mm) extracapsular spread is not an adverse predictor of outcome in metastatic squamous cell carcinoma of the oral cavity. 

Wreesmann VB, Ghossein RA, Carlson D, Ganly I, Palmer F, Montero P, Shah JP, Patel SG. 

Presented at the AHNS 2014 Annual Meeting, July 2014, New York, New York.

Books, Chapters:

• Molecular Biology as applied to Head and Neck Oncology

Wreesmann VB, Singh B.

Stell and Maran's Textbook of Head and Neck Surgery and Oncology

Fifth Edition

Chapter, edited by John Watkinson and Ralph Gilbert

• Molecular-Cytogenetic Characterization of Head and Neck Cancer: Identification of molecular prognostic factors and targets of therapy

Wreesmann VB, Singh B.

Book, Amsterdam 2004

Reviewed in: Head and Neck: Volume 29, Issue 1, pages 82–83, January 2007

• Open Conservation Surgery for Laryngeal Cancer

Wreesmann VB, Ganly I

Scott-Brown's Otorhinolaryngology and Head and Neck Surgery, Eighth Edition

Chapter 27

CRC Press, Taylor-Francis Group, June 12th, 2018

• Molecular Oncology

Wreesmann V.B.

Self-Assessment in Head and Neck Surgery and Oncology, First Edition

Chapter 21

Elsevier 2014

Research grants:

Netherlands Cancer Institute “Startgeld” Grant 2008

Project: Fanconi anemia in head and neck cancer

Principal investigators: Wreesmann VB, van den Brekel MW, Balm AJM, Vens C.

Amount granted: 300.000 euro

Dr Nabil Ragaei Kamel jest bardzo doświadczonym okulistą o zróżnicowanym zakresie specjalizacji w opiece nad oczami. Rocznie wykonuje ponad 3600 operacji, wykorzystując najnowocześniejszą technologię do całkowicie laserowych operacji oczu. Takie podejście zapewnia pacjentom bezpieczną, skuteczną i szybką rekonwalescencję. Jego niezwykły wkład w dziedzinę okulistyki przyniósł mu tytuł Lekarza Roku.

Operacje świadczone

• Wstrzyknięcia botoksu
• Trabkuloplastyka laserowa
• Witrektomia
• Operacja oka metodą LASIK
• Operacja laserowa oka
• Wszczepienie soczewek wewnątrzgałkowych
• Operacja zeza
• Operacja zaćmy (jedno oko)
• Operacja oczu ReLEx SMILE
• Irydotomia laserowa
• Trabekulotomia
• Operacja oka metodą LASEK
• Operacja zaćmy z wszczepieniem soczewki multifokalnej
• Operacja zaćmy z wymianą soczewki wewnątrzgałkowej

Nagrody

• Lekarz Roku w Okulistyce

Doświadczenie zawodowe:

• Od lutego 2019 r. do chwili obecnej: Kierownik Oddziału Radioterapii Onkologicznej, Centrum Terapii Protonowej Quirónsalud, Madryt, Hiszpania.
• 2017-18: Starszy specjalista radioterapii onkologicznej, Klinika MAASTRO – ZON-PTC (Zuid-Oost Nederland Protonen Therapie Centrum), Maastricht, Holandia.
• 2014-17: Starszy radioonkolog, Oddział Radioterapii Onkologicznej, Szpital Uniwersytecki w Genewie, Genewa, Szwajcaria.
• 2005-14: Starszy lekarz w dziedzinie radioterapii onkologicznej, Centrum Terapii Protonowej, Instytut Paula Scherrera, Villigen, Szwajcaria.
• 2006: Staż kliniczny w zakresie radioterapii onkologicznej protonowej, Francis H. Burr Proton Therapy Center, Oddział Radioterapii Onkologicznej, Massachusetts General Hospital, Boston, MA, USA.
• 2005: Lekarz specjalista w dziedzinie radioterapii onkologicznej, Oddział Radioterapii Onkologicznej, Szpital Uniwersytecki w Lozannie, Lozanna, Szwajcaria.
• 2002-2004: Specjalista medycyny radioterapii onkologicznej, Oddział Radioterapii Onkologicznej, Szpital Uniwersytecki w Genewie, Genewa, Szwajcaria.
• 1999-2002: Asystent lekarza w dziedzinie radioterapii onkologicznej, Oddział radioterapii onkologicznej, Szpital Uniwersytecki Vall d'Hebron, Autonomiczny Uniwersytet w Barcelonie, Barcelona, Hiszpania.
• 1999: Asystent lekarza w dziedzinie radioterapii onkologicznej, Oddział radioterapii onkologicznej, Szpital Uniwersytecki Sant Pau, Uniwersytet Autonomiczny w Barcelonie, Barcelona, Hiszpania.
• 1994-98: Rezydentura w zakresie radioterapii onkologicznej, Szpital Uniwersytecki Sant Pau, Uniwersytet Autonomiczny w Barcelonie, Barcelona, Hiszpania.

Edukacja:

• 1984-91: Ukończenie studiów na kierunku medycyna i chirurgia na Wydziale Lekarskim Uniwersytetu Autonomicznego w Barcelonie, Barcelona, Hiszpania.
• Od 2018 r.: doktorantka, Uniwersytet w Maastricht, Holandia.

Publikacje:

Dr Ares jest autorem 34 artykułów naukowych opublikowanych w recenzowanych czasopismach medycznych.

Jej bogate doświadczenie międzynarodowe i zaangażowanie w innowacyjne metody leczenia czynią ją wiodącą ekspertką w dziedzinie terapii protonowej i radioterapii onkologicznej.

Doświadczenie zawodowe:

• Od lutego 2019 r. do chwili obecnej: Kierownik Oddziału Radioterapii Onkologicznej, Centrum Terapii Protonowej Quirónsalud, Madryt, Hiszpania.

• 2017-18 Starszy specjalista radioterapii onkologicznej, Klinika MAASTRO – ZON-PTC (Zuid-Oost Nederland Protonen Therapie Centrum), Maastricht, Holandia.
• 2014-17 Starszy radioonkolog, Oddział Radioterapii Onkologicznej, Szpital Uniwersytecki w Genewie, Genewa, Szwajcaria.
• 2005-14 Starszy lekarz w dziedzinie radioterapii onkologicznej, Centrum Terapii Protonowej, Instytut Paula Scherrera, Villigen, Szwajcaria.
• 2006 Staż kliniczny w zakresie radioterapii onkologicznej protonowej, Centrum Terapii Protonowej im. Francisa H. Burra, Oddział Radioterapii Onkologicznej, Szpital Ogólny w Massachusetts, Boston, MA, USA.
• 2005: Lekarz specjalista w dziedzinie radioterapii onkologicznej, Oddział Radioterapii Onkologicznej, Szpital Uniwersytecki w Lozannie, Lozanna, Szwajcaria.
• 2002-2004 Specjalista medycyny radioterapii onkologicznej, Oddział Radioterapii Onkologicznej, Szpital Uniwersytecki w Genewie, Genewa, Szwajcaria.
• 1999-2002 Asystent lekarza w dziedzinie radioterapii onkologicznej, Oddział radioterapii onkologicznej, Szpital Uniwersytecki Vall d'Hebron, Autonomiczny Uniwersytet w Barcelonie, Barcelona, Hiszpania.
• 1999 Asystent lekarza w dziedzinie radioterapii onkologicznej, Oddział radioterapii onkologicznej, Szpital Uniwersytecki Sant Pau, Uniwersytet Autonomiczny w Barcelonie, Barcelona, Hiszpania.
• 1994-98 Rezydent w zakresie radioterapii onkologicznej, Szpital Uniwersytecki Sant Pau, Uniwersytet Autonomiczny w Barcelonie, Barcelona, Hiszpania.

Edukacja:

• 1984-91: Ukończenie studiów na kierunku medycyna i chirurgia na Wydziale Lekarskim Uniwersytetu Autonomicznego w Barcelonie, Barcelona, Hiszpania.
• Od 2018 r.: doktorantka, Uniwersytet w Maastricht, Holandia.

Publikacje:

Dr Ares jest autorem 34 artykułów naukowych opublikowanych w recenzowanych czasopismach medycznych.

Jej bogate doświadczenie międzynarodowe i zaangażowanie w innowacyjne metody leczenia czynią ją wiodącą ekspertką w dziedzinie terapii protonowej i radioterapii onkologicznej.

Dr Luis Madero jest pediatrą onkologiem z 37-letnim doświadczeniem w leczeniu chorób krwi, przeszczepów szpiku kostnego, terapii ablacyjnej i innych chorób. Jest członkiem kilku stowarzyszeń i ma duże doświadczenie w swojej dziedzinie.

W naszym biurze znajduje się CV lekarza dla każdego, kto tego wymaga

Głównym aspektem jest największe doświadczenie Dra Basurco jako medycyny estetycznej w Hiszpanii (ponad 15 lat), aplikowanie na różnych kongresach w celu ciągłego postępu w medycynie estetycznej. Jest ona bardzo oddaną osobą innowacji estetycznych, bardzo ciekawą osobą, która zawsze trafia na skórę pacjenta. Przyzwyczajona do pracy z pacjentami zagranicznymi, stara się dać im najlepszą opcję dla Twojej sytuacji. Nasza klinika zweryfikowała wszystkie produkty i techniki z Dra Basurco pracuje w naszej klinice

Dr. Ellen Christiaanse is an expert in alternative healing. She combines evidence-based methods with holistic practices. She earned a Doctorate in Information Systems from MIT. She also holds a Master’s in Organizational Psychology.

Dr. Christiaanse is certified as a Reiki Master, Yin Yoga Teacher, Sound Therapy Healer, and Horse-Assisted Coach. She has led more than 100 wellness retreats. These include Yoga, Meditation, Detox, and Women’s programs. She is known for her innovative healing techniques and dedication to integrative health. Her client satisfaction rate is over 95%.